SCHEMBL1067679

SCHEMBL1067679

CCOC(=O)/C=C(/C)Oc1cccc(C)c1

nearest known ligand 0.57

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.57
TDP1 Q9NUW8 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
GAA P10253 1/20 0.43
MAPT P10636 3/20 0.42
MEN1 O00255 2/20 0.41
KMT2A Q03164 2/20 0.41
KDM4E B2RXH2 1/20 0.41
CRHBP P24387 1/20 0.41
CRHR2 Q13324 1/20 0.41
ALOX15 P16050 1/20 0.41
MAPK1 P28482 1/20 0.41
HSD17B10 Q99714 1/20 0.41
ALOX5 P09917 1/20 0.41
POLB P06746 1/20 0.41
BCHE P06276 1/20 0.40
ALDH1A1 P00352 1/20 0.40
PPARG P37231 1/20 0.40
SMN1; SMN2 Q16637 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1067677 1.00 LMNA (0.57) LMNATDP1L3MBTL1GAAMAPT
SCHEMBL1067680 1.00 LMNA (0.57) LMNATDP1L3MBTL1GAAMAPT
SCHEMBL1069254 0.87 ALDH1A1 (0.46) LMNATDP1L3MBTL1MAPTMEN1
SCHEMBL1064150 0.87 ALDH1A1 (0.48) LMNATDP1L3MBTL1MAPTMAPK1
SCHEMBL1064148 0.87 ALDH1A1 (0.48) LMNATDP1L3MBTL1MAPTMAPK1
SCHEMBL1067349 0.87 ALDH1A1 (0.48) LMNATDP1L3MBTL1MAPTMAPK1
SCHEMBL1069256 0.87 ALDH1A1 (0.46) LMNATDP1L3MBTL1MAPTMEN1
SCHEMBL1067379 0.86 KDM4E (0.42) LMNATDP1L3MBTL1GAAMAPT
SCHEMBL1068753 0.86 MAPT (0.47) LMNAL3MBTL1GAAMAPTKMT2A
SCHEMBL1067566 0.86 MAPT (0.42) LMNAGAAMAPTKMT2AKDM4E

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2274297-B1 PYRROLIDINONE GLUCOKINASE ACTIVATORS HOFFMANN LA ROCHE (CH) 2012-05-09 EP disclosed
EP-2274297-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. Hoffmann-La Roche AG (CH) 2011-01-19 EP disclosed
US-7741327-B2 Pyrrolidinone glucokinase activators HOFFMANN-LA ROCHE INC. (US) 2010-06-22 US disclosed
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS BERTHEL STEVEN JOSEPH 2009-10-22 US disclosed
WO-2009127546-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS F. HOFFMANN-LA ROCHE AG (CH) 2009-10-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090264445-A1 PYRROLIDINONE GLUCOKINASE ACTIVATORS GCKR, GCK, PDK2 LMNA 3936/4885TDP1 1793/4885L3MBTL1 4431/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.